Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Aurora kinase inhibitors for inhibiting mitotic progression
US9765076B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9765076-B2 |
| Application number | US-201414514687-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 15, 2014 |
| Priority date | Nov 16, 2006 |
| Publication date | Sep 19, 2017 |
| Grant date | Sep 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A process for preparing the compound (1): said process comprising reacting a compound of formula (iv): with a compound of formula (v): 2. The process of claim 1 , further comprising converting the compound (1) into a sodium salt thereof. 3. The process of claim 2 , wherein said converting comprises reacting the compound (1) with sodium hydroxide. 4. The process of claim 1 , wherein said reacting is carried out in the presence of methanol and potassium carbonate. 5. The process of claim 4 , further comprising converting the compound (1) into a sodium salt thereof. 6. The process of claim 5 , wherein said converting comprises reacting the compound (1) with sodium hydroxide. 7. A process for preparing sodium 4-{[9-chloro-7-(2-fluoro-6-methoxy phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, comprising reacting 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid with sodium hydroxide.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9765076B2 cover?
- The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
- Who is the assignee on this patent?
- Millennium Pharm Inc, Millenium Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).